Page 38 - Read Online

Page 16 of 17 Li et al. Hepatoma Res. 2025;11:25 https://dx.doi.org/10.20517/2394-5079.2025.63

41. Collettini F, Brangsch J, Reimann C, et al. Hepatic radiofrequency ablation: monitoring of ablation-induced macrophage recruitment in
the periablational rim using SPION-enhanced macrophage-specific magnetic resonance imaging. Invest Radiol. 2021;56:591-8. DOI
PubMed
42. Liu X, Zhang W, Xu Y, et al. Targeting PI3Kγ/AKT pathway remodels LC3-associated phagocytosis induced immunosuppression
after radiofrequency ablation. Adv Sci. 2022;9:e2102182. DOI PubMed PMC
43. Mauri G, Porazzi E, Cova L, et al. Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency
ablation: clinical impact and health technology assessment. Insights Imaging. 2014;5:209-16. DOI PubMed PMC
44. Bansal S, Gui J, Merrill C, Wong JK, Burak KW, Wilson SR. Contrast-enhanced US in local ablative therapy and secondary
surveillance for hepatocellular carcinoma. Radiographics. 2019;39:1302-22. DOI PubMed
45. Fite BZ, Wang J, Ghanouni P, Ferrara KW. A review of imaging methods to assess ultrasound-mediated ablation. BME Front.
2022;2022:9758652. DOI PubMed PMC
46. Shyn PB, Casadaban LC, Sainani NI, et al. Intraprocedural ablation margin assessment by using ammonia perfusion PET during FDG
PET/CT-guided liver tumor ablation: a pilot study. Radiology. 2018;288:138-45. DOI PubMed
47. Jiang Q, Zeng Y, Xu Y, et al. Ultrasound molecular imaging as a potential non-invasive diagnosis to detect the margin of
hepatocarcinoma via CSF-1R targeting. Front Bioeng Biotechnol. 2020;8:783. DOI PubMed PMC
48. Kan X, Zhou G, Zhang F, et al. Interventional optical imaging permits instant visualization of pathological zones of ablated tumor
periphery and residual tumor detection. Cancer Res. 2021;81:4594-602. DOI PubMed PMC
18
49. Mateva G, Handzhiev S, Kostadinova I. The role of F-FDG PET/CT in evaluating the efficacy of radiofrequency ablation in
metastatic and primary liver tumors: preliminary results. Mol Imaging Radionucl Ther. 2021;30:1-7. DOI PubMed PMC
50. Li K, Su ZZ, Xu EJ, Ju JX, Meng XC, Zheng RQ. Improvement of ablative margins by the intraoperative use of CEUS-CT/MR image
fusion in hepatocellular carcinoma. BMC Cancer. 2016;16:277. DOI PubMed PMC
51. Liu B, Zhang Y, Chen H, Li W, Tsochatzis E. The combination of transcatheter arterial chemoembolisation (TACE) and thermal
ablation versus TACE alone for hepatocellular carcinoma. Cochrane Database Syst Rev. 2022;1:CD013345. DOI PubMed PMC
52. Wei W, Jian PE, Li SH, et al. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma
patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun.
2018;38:61. DOI PubMed PMC
53. Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a
randomized controlled study. Clin Cancer Res. 2018;24:2074-81. DOI PubMed
54. Guo B, Chen Q, Liu Z, Chen X, Zhu P. Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas
and prospects. Front Oncol. 2023;13:1098958. DOI PubMed PMC
55. Horkan C, Dalal K, Coderre JA, et al. Reduced tumor growth with combined radiofrequency ablation and radiation therapy in a rat
breast tumor model. Radiology. 2005;235:81-8. DOI PubMed
56. Young S, Golzarian J. Locoregional therapies in the treatment of 3- to 5-cm hepatocellular carcinoma: critical review of the literature.
AJR Am J Roentgenol. 2020;215:223-34. DOI PubMed
57. Hendriks P, Rietbergen DDD, van Erkel AR, et al; Dutch Hepatocellular and Cholangiocarcinoma Group. Adjuvant holmium-166
radioembolization after radiofrequency ablation in early-stage hepatocellular carcinoma patients: a dose-finding study (HORA EST
HCC trial). Eur J Nucl Med Mol Imaging. 2024;51:2085-97. DOI PubMed PMC
58. Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
Gastroenterology. 2015;148:1383-91.e6. DOI PubMed
59. Su JY, Li JR, Pan LX, et al. Tertiary lymphoid structures in HCC: influence on immune cell profiles in tumors and on efficacy of
adjuvant PD-1 inhibitor therapy after hepatectomy. Hepatology. 2025;Epub ahead of print. DOI PubMed
60. Wang X, Liu G, Chen S, et al. Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular
carcinoma: a propensity score matching analysis. Int J Hyperthermia. 2021;38:1519-28. DOI PubMed
61. Chow P, Chen M, Cheng A, et al. Abstract CT003: IMbrave050: phase 3 study of adjuvant atezolizumab + bevacizumab versus active
surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation. Cancer
Research. 2023;83:CT003. DOI
62. Zhu AX, Abbas AR, de Galarreta MR, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination
with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28:1599-611. DOI PubMed
63. Llovet JM, Pinyol R, Yarchoan M, et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat Rev Clin Oncol.
2024;21:294-311. DOI PubMed PMC
64. Zhang X, Zhou Y, Chen C, et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing
PD-1 inhibition. J Immunother Cancer. 2019;7:322. DOI PubMed PMC
65. Chen S, Shen B, Wu Y, et al. The relationship between the efficacy of thermal ablation and inflammatory response and immune status
in early hepatocellular carcinoma and the progress of postoperative adjuvant therapy. Int Immunopharmacol. 2023;119:110228. DOI
PubMed
66. Feng X, Xu R, Du X, et al. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular
carcinoma: a multicenter retrospective cohort study. Am J Gastroenterol. 2014;109:1891-9. DOI PubMed
67. Bruix J, Takayama T, Mazzaferro V, et al; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or
ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344-54. DOI PubMed